The compound, SB-0110, was tested in rodent and non-human primate models of Parkinson’s disease during preclinical tests.

Parkinson's disease (PD) is the second most common form of neurodegenerative disease and afflicts more than 10 million people worldwide. While current therapies address disease symptoms, they do not ...

New clinical data from the STEM-PD Phase I/II clinical trial have been presented at the ISSCR 2026 Annual Meeting. The study ...

Parkinson’s disease currently affects nearly one million Americans with no specific known cause and no cure. Treatments have come a long way over the past few decades focusing on managing symptoms and ...

Dopamine agonists such as pramipexole, ropinirole, rotigotine, and apomorphine have long been recommended as initial therapy for younger patients with Parkinson’s disease, typically those younger than ...

For many people with Parkinson's disease, the body stops moving the way it used to. A hand may tremble at rest. Muscles may ...

Add Yahoo as a preferred source to see more of our stories on Google. Dr. Stephen Strittmatter (Contributed photo / Yale University) A Yale-led team of scientists has joined a worldwide effort to find ...

Discover why Parkinson's disease affects men more than women and the genetic factors involved. Learn about new research ...

Experts advocate for greater access to incision-free MRgFUS treatment for Parkinson’s in India, enhancing patient quality of ...

GRAND RAPIDS, Mich. — April is Parkinson's Awareness Month. More than 10 million people live with the progressive brain disorder across the world. It causes stiffness, tremors, trouble moving and more ...

Disease progression in people with Parkinson's disease can be accurately monitored using sensors, removing some of the ...

A study published in Cannabis and Cannabinoid Research examined the effects of medical cannabis on patients diagnosed with ...